Adaptimmune/Genentech Deal Gives Powerful Push To Solid Tumor Cell Therapies
Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.
You may also be interested in...
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
Merck & Co's proposed acquisition of Acceleron and a couple of big purchases from Sanofi drove up the value of the sector's M&A activities, according to the latest report from Biomedtracker
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.